BeOne director sells ADS for tax withholding

BeOne Medicines Ltd. director Alessandro Riva reported a small tax‑related share sale.

Rhea-AI Filing Summary

BeOne Medicines Ltd. director Alessandro Riva reported a small tax‑related share sale. On 2026-05-22, he sold 212 American Depositary Shares of BeOne Medicines in an open-market transaction at an average price of $309.5142 per ADS. A footnote explains the sale was mandated under a tax withholding provision tied to the vesting of a restricted share unit award, meaning it was executed to cover tax obligations rather than as a discretionary portfolio move. Each American Depositary Share represents 13 Ordinary Shares. After these transactions, a holding entry shows Riva with 54,184 Ordinary Shares held directly.

Insider Trade Summary

Net Seller: 212 shares

Net Sell 2 txns

Insider Riva Alessandro

Role Director

Sold 212 shs ($66K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares	212	$309.5142	$66K
holding	Ordinary Shares	--	--	--

Holdings After Transaction: American Depositary Shares — 0 shares (Direct); Ordinary Shares — 54,184 shares (Direct)

Footnotes (2)

1. F1. Each American Depositary Share represents 13 Ordinary Shares.
2. F2. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

Key Figures

ADS sold: 212 American Depositary Shares Sale price per ADS: $309.5142 per ADS Ordinary Shares held: 54,184 Ordinary Shares +1 more

4 metrics

ADS sold 212 American Depositary Shares Open-market sale on 2026-05-22

Sale price per ADS $309.5142 per ADS Mandatory tax withholding sale

Ordinary Shares held 54,184 Ordinary Shares Direct holdings following reported activity

ADS to Ordinary Share ratio 1 ADS = 13 Ordinary Shares Equity structure as disclosed in footnote

Key Terms

American Depositary Shares, restricted share unit, mandatory tax withholding provision, change in control

4 terms

American Depositary Shares financial

"The sale was effected in American Depositary Shares of BeOne Medicines."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

restricted share unit financial

"The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement."

A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.

mandatory tax withholding provision financial

"The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement."

change in control financial

"Unvested securities are subject to accelerated vesting upon a change in control or certain termination events."

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BeOne Medicines (ONC) director Alessandro Riva report?

Director Alessandro Riva reported selling 212 American Depositary Shares of BeOne Medicines. The sale was executed in connection with tax withholding on a vesting restricted share unit award, rather than as a discretionary portfolio sale, according to the filing’s footnotes.

At what price did Alessandro Riva’s BeOne Medicines (ONC) ADS transaction occur?

The reported transaction in BeOne Medicines American Depositary Shares occurred at an average price of $309.5142 per ADS. This price reflects the execution level for the mandatory tax withholding sale tied to the vesting of a restricted share unit award.

How many BeOne Medicines (ONC) American Depositary Shares did Alessandro Riva sell?

Alessandro Riva sold 212 American Depositary Shares of BeOne Medicines. The Form 4 notes this as an open-market sale coded “S,” executed to satisfy tax withholding obligations associated with a vesting restricted share unit grant.

What does each BeOne Medicines (ONC) American Depositary Share represent?

Each American Depositary Share of BeOne Medicines represents 13 Ordinary Shares. This ratio is disclosed in the Form 4 footnotes and helps investors understand how ADS holdings relate to the company’s underlying Ordinary Shares listed in its home market.

Was Alessandro Riva’s BeOne Medicines (ONC) sale part of tax withholding?

Yes. A footnote states the ADS sale was effected under a mandatory tax withholding provision in Riva’s restricted share unit award agreement, in connection with vesting, indicating the transaction was driven by tax obligations rather than a discretionary decision to sell.

What ongoing equity exposure does Alessandro Riva report in BeOne Medicines (ONC)?

Following the reported activity, a holding line shows Alessandro Riva with 54,184 Ordinary Shares of BeOne Medicines held directly. This reflects his continuing equity exposure separate from the small ADS sale used to satisfy tax withholding on a vesting RSU grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 05:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Riva Alessandro

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL 4051

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								54,184	D
American Depositary Shares(1)	05/22/2026		S(2)		212	D	$309.5142	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)